Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 4;431(1):88-101.
doi: 10.1016/j.jmb.2018.05.044. Epub 2018 Jun 7.

CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool

Affiliations
Review

CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool

Carolyn Brokowski et al. J Mol Biol. .

Abstract

With the emergence of CRISPR technology, targeted editing of a wide variety of genomes is no longer an abstract hypothetical, but occurs regularly. As application areas of CRISPR are exceeding beyond research and biomedical therapies, new and existing ethical concerns abound throughout the global community about the appropriate scope of the systems' use. Here we review fundamental ethical issues including the following: 1) the extent to which CRISPR use should be permitted; 2) access to CRISPR applications; 3) whether a regulatory framework(s) for clinical research involving human subjects might accommodate all types of human genome editing, including editing of the germline; and 4) whether international regulations governing inappropriate CRISPR utilization should be crafted and publicized. We conclude that moral decision making should evolve as the science of genomic engineering advances and hold that it would be reasonable for national and supranational legislatures to consider evidence-based regulation of certain CRISPR applications for the betterment of human health and progress.

Keywords: CRISPR–Cas9; bioengineering; genetic engineering; genome editing; research ethics.

PubMed Disclaimer

References

    1. Cyranoski D. CRISPR gene-editing tested in a person for the first time. Nature. 2016;539:479. - PubMed
    1. CRISPR to debut in clinical trials. [cited 2018 May 15];Kwon D. Israel Molecular Medicine. 2017 Available from: http://www.molecular-medicine-israel.co.il/crispr-debut-clinical-trials/
    1. ClinicalTrials.gov. [cited 2018 May 20];U.S. National Library of medicine. 2018 Available from: https://clinicaltrials.gov/ct2/results?cond=&term=CRISPR&cntry=&state=&c...
    1. The L. Editing the human genome: balancing safety and regulation. Lancet. 2018;391:402. - PubMed
    1. Scheufele DA, Xenos MA, Howell EL, Rose KM, Brossard D, Hardy BW. U.S. attitudes on human genome editing. Science. 2017;357:553–4. - PubMed

Publication types

MeSH terms